Scotiabank analyst Louise Chen upgraded Sarepta (SRPT) to Outperform from Sector Perform with an $80 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Buy Rating on Sarepta Therapeutics Driven by FDA Platform Technology Designation
- Sarepta granted platform technology designation by FDA for rAAVrh74 viral vector
- Sarepta management to meet with Oppenheimer
- Optimistic Outlook for Sarepta Therapeutics Amid Positive Developments in ENVISION Study and Strategic Partnerships
- Sarepta Therapeutics: Navigating Clinical Holds and Regulatory Challenges Amidst Market Expansion Uncertainty